Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Non-Current Deffered Revenue (2023 - 2025)

Historic Non-Current Deffered Revenue for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $3.0 million.

  • Beta Bionics' Non-Current Deffered Revenue changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2024, which is 62941.18% up from last year.
  • As of Q3 2025, Beta Bionics' Non-Current Deffered Revenue stood at $3.0 million.
  • Beta Bionics' 5-year Non-Current Deffered Revenue high stood at $3.0 million for Q3 2025, and its period low was $255000.0 during Q4 2023.
  • For the 3-year period, Beta Bionics' Non-Current Deffered Revenue averaged around $2.0 million, with its median value being $2.3 million (2025).
  • Data for Beta Bionics' Non-Current Deffered Revenue shows a peak YoY increase of 62941.18% (in 2024) and a maximum YoY decrease of 62941.18% (in 2024) over the last 5 years.
  • Over the past 3 years, Beta Bionics' Non-Current Deffered Revenue (Quarter) stood at $255000.0 in 2023, then soared by 629.41% to $1.9 million in 2024, then soared by 60.54% to $3.0 million in 2025.
  • Its Non-Current Deffered Revenue was $3.0 million in Q3 2025, compared to $2.7 million in Q2 2025 and $2.3 million in Q1 2025.